HBED-CC has been successfully applied in the theranostics of prostate cancer when conjugated to the prostate-specific membrane antigen (PSMA) (Virgolini et al., 2017) but the combination with oxygen sensitive groups is yet to been investigated. The gene discussed is FOLH1; the disease is Familial prostate cancer.